Current Oncology (Mar 2021)

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

  • Anca Prica,
  • Annette E. Hay,
  • Michael Crump,
  • Nicole Mittmann,
  • Lois E. Shepherd,
  • Ralph M. Meyer,
  • Kevin I. Imrie,
  • Nancy Risebrough,
  • Marina Djurfeldt,
  • Bingshu E. Chen,
  • Matthew C. Cheung

DOI
https://doi.org/10.3390/curroncol28020119
Journal volume & issue
Vol. 28, no. 2
pp. 1256 – 1261

Abstract

Read online

We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers.

Keywords